Please login to the form below

Not currently logged in
Email:
Password:

Chronic Myelogenous Leukaemia

This page shows the latest Chronic Myelogenous Leukaemia news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s leukaemia drug Mylotarg backed for use in EU

Pfizer’s leukaemia drug Mylotarg backed for use in EU

Pfizer’ s leukaemia drug Mylotarg backed for use in EU. The CHMP’s positive opinion could see the drug return to market after almost eight years. ... Kineret (anakinra) in rare inflammatory condition Still’s disease; and Pfizer’s Bosulif

Latest news

  • Novartis pulls EMA application for expanded Tasigna use Novartis pulls EMA application for expanded Tasigna use

    The company said it no longer wishes to seek approval for its cancer treatment Tasigna (nilotinib) in patients with Philadelphia-chromosome-positive chronic myelogenous leukaemia (CML) who did not achieve 'complete ... Tasigna is already approved in the

  • Novartis' Tasigna tops Glivec in long-term trial Novartis' Tasigna tops Glivec in long-term trial

    Novartis' Tasigna tops Glivec in long-term trial. Boost ahead of patent expiry for leukaemia drug. ... New phase III data has revealed that Novartis' chronic myelogenous leukaemia (CML) treatment Tasigna is more effective than forerunner Glivec over the

  • Scotland first in UK to back Pfizer's Inlyta Scotland first in UK to back Pfizer's Inlyta

    The Scottish agency concurred with earlier NICE guidance however and did not support the use of Pfizer's Bosulif (bosutinib) as a back-up treatment for chronic phase, accelerated phase, and ... blast phase Philadelphia chromosome-positive chronic

  • Roche wins conditional EU approval for cancer drug Erivedge Roche wins conditional EU approval for cancer drug Erivedge

    Other drugs to receive conditional approval in Europe in recent years include GlaxoSmithKline's (GSK) renal cell carcinoma treatment Votrient (pazopanib), Pfizer's chronic myelogenous leukaemia (CML) treatment Bosulif (bosutinib) and

  • Pfizer gets CHMP backing for leukaemia drug bosutinib Pfizer gets CHMP backing for leukaemia drug bosutinib

    Pfizer gets CHMP backing for leukaemia drug bosutinib. Provides option for patients resistant to tyrosine kinase inhibitors. ... Pfizer moved a step closer to getting EU a green light for its chronic myelogenous leukaemia (CML) drug bosutinib last week

More from news
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Chronic Myelogenous Leukaemia (CML) study in the US. ... Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC),

  • Research Partnership

    Prescription medicines. Within prescription medicines, we have therapeutic specialists and experience in a broad range of therapy areas from chronic illnesses to rare diseases. ... new Chronic Myelogenous Leukaemia (CML) study in the US.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics